FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555989920> ?p ?o ?g. }

• W2555989920 endingPage "1019" @default.
• W2555989920 startingPage "1019.2" @default.
• W2555989920 abstract "<h3>Background</h3> Staphylococcal protein A (SpA) is a bacterial B-cell superantigen that binds with high affinity to the Fc region of most immunoglobulins (Igs) and to the Fab framework region of Igs in the V_H3 gene family. PRTX-100, a highly purified form of SpA, has exhibited an acceptable safety profile when administered intravenously to small numbers of subjects at doses of up to 12 μg/kg.¹ SpA forms multimeric Ig complexes (MIgCs) with human antibodies which interact with and modulate cells of the monocytic lineage via FcR1 receptors.² However, the effects of SpA in rheumatoid arthritis (RA) are not fully understood. <h3>Objectives</h3> To expand the safety experience of parenteral PRTX-100 given to patients with RA, including retreatment. To describe PRTX-100 immunogenicity and pharmacodynamics as well as the feasibility of ultrasound joint count measurements. <h3>Methods</h3> This open-label trial enrolled 11 seropositive patients with RA who had previously participated in a Phase I trial¹ and responded (n=9) or had been given placebo (n=2). Patients were treated with 6 μg/kg PRTX-100 with four weekly intravenous infusions followed by five monthly infusions. Safety and disease activity were monitored monthly. Anti-PRTX-100 antibodies were measured. Patients were evaluated by standard clinical assessments and by ultrasound power Doppler joint counts (UPD).³ Pharmacodynamic alterations in MIgC concentrations were assessed via cryoglobulin levels. <h3>Results</h3> The preliminary results indicated that PRTX-100 exhibited an acceptable safety profile. Adverse events (AEs) included fatigue (9% of patients), and headache (9%). Worsening of RA following initial infusions were observed in 82% of patients but diminished with subsequent infusions of PRTX-100. One patient discontinued therapy due to worsening of RA symptoms. One patient discontinued treatment due to perceived lack of improvement. No serious AEs were reported. At study day 196, 1 month after final infusion, all 11 patients demonstrated a reduction of DAS28CRP. There was a reduction in the UPD score of 26% (p=0.0054) and a correlation between the UPD and DAS28CRP of r=0.630 (p<0.0001). In addition, 55% of patients demonstrated increases in their MIgCs during treatment <h3>Conclusions</h3> Treatment with PRTX-100 in nine patients for the second time and two patients for the first time demonstrated an acceptable safety profile. A single subject discontinued the trial due to worsening of RA symptoms, although RA disease activity was improved in the majority of patients by the end of the study compared to baseline levels. Some subjects exhibited an increase in MIgCs after infusion of PRTX-100. The incorporation of ultrasound joint count methodology into small open-label trials might offer enhanced assessment of clinical efficacy. <h3>References</h3> Wiesenhutter CW, et al. Arthritis Rheum 2014;#1487. MacLellan LM, et al. Arthritis Rheum 2011;63:3897–907. Kawashiri SY, et al. Rheumatology 2011;50:962–5. <h3>Acknowledgement</h3> C. Wiesenhutter Grant/research support from Protalex Inc. <h3>Disclosure of Interest</h3> None declared" @default.
• W2555989920 created "2016-11-30" @default.
• W2555989920 creator A5048557854 @default.
• W2555989920 date "2016-06-01" @default.
• W2555989920 modified "2023-10-14" @default.
• W2555989920 title "AB0343 Treatment of Rheumatoid Arthritis Patients with Parenteral Staphylococcal Protein A (PRTX-100): An Open-Label Single-Site Extension Trial" @default.
• W2555989920 doi "https://doi.org/10.1136/annrheumdis-2016-eular.2540" @default.
• W2555989920 hasPublicationYear "2016" @default.
• W2555989920 type Work @default.
• W2555989920 sameAs 2555989920 @default.
• W2555989920 citedByCount "0" @default.
• W2555989920 crossrefType "journal-article" @default.
• W2555989920 hasAuthorship W2555989920A5048557854 @default.
• W2555989920 hasConcept C111113717 @default.
• W2555989920 hasConcept C112705442 @default.
• W2555989920 hasConcept C126322002 @default.
• W2555989920 hasConcept C142724271 @default.
• W2555989920 hasConcept C159654299 @default.
• W2555989920 hasConcept C203014093 @default.
• W2555989920 hasConcept C204787440 @default.
• W2555989920 hasConcept C27081682 @default.
• W2555989920 hasConcept C2777077863 @default.
• W2555989920 hasConcept C2777575956 @default.
• W2555989920 hasConcept C2780868878 @default.
• W2555989920 hasConcept C71924100 @default.
• W2555989920 hasConcept C90924648 @default.
• W2555989920 hasConceptScore W2555989920C111113717 @default.
• W2555989920 hasConceptScore W2555989920C112705442 @default.
• W2555989920 hasConceptScore W2555989920C126322002 @default.
• W2555989920 hasConceptScore W2555989920C142724271 @default.
• W2555989920 hasConceptScore W2555989920C159654299 @default.
• W2555989920 hasConceptScore W2555989920C203014093 @default.
• W2555989920 hasConceptScore W2555989920C204787440 @default.
• W2555989920 hasConceptScore W2555989920C27081682 @default.
• W2555989920 hasConceptScore W2555989920C2777077863 @default.
• W2555989920 hasConceptScore W2555989920C2777575956 @default.
• W2555989920 hasConceptScore W2555989920C2780868878 @default.
• W2555989920 hasConceptScore W2555989920C71924100 @default.
• W2555989920 hasConceptScore W2555989920C90924648 @default.
• W2555989920 hasIssue "Suppl 2" @default.
• W2555989920 hasLocation W25559899201 @default.
• W2555989920 hasOpenAccess W2555989920 @default.
• W2555989920 hasPrimaryLocation W25559899201 @default.
• W2555989920 hasRelatedWork W1934038313 @default.
• W2555989920 hasRelatedWork W1998726531 @default.
• W2555989920 hasRelatedWork W2062826169 @default.
• W2555989920 hasRelatedWork W2411114470 @default.
• W2555989920 hasRelatedWork W2461786476 @default.
• W2555989920 hasRelatedWork W2799768029 @default.
• W2555989920 hasRelatedWork W3029503209 @default.
• W2555989920 hasRelatedWork W3159937175 @default.
• W2555989920 hasRelatedWork W428203746 @default.
• W2555989920 hasRelatedWork W4319655731 @default.
• W2555989920 hasVolume "75" @default.
• W2555989920 isParatext "false" @default.
• W2555989920 isRetracted "false" @default.
• W2555989920 magId "2555989920" @default.
• W2555989920 workType "article" @default.